Evaluation of IC50 levels immediately after treatment with anticancer reagents using a real‑time cell monitoring device

  • Authors:
    • Mai Hazekawa
    • Takuya Nishinakagawa
    • Tomoyo Kawakubo‑Yasukochi
    • Manabu Nakashima
  • View Affiliations

  • Published online on: August 13, 2019     https://doi.org/10.3892/etm.2019.7876
  • Pages: 3197-3205
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A real‑time cell‑monitoring analysis (RTCA) system was previously developed based on the change in impedance when cells attach and spread in a culture dish coated with a gold microelectrode array. However, the potential applications of this system have not yet been fully demonstrated. The purpose of this study was to test the utility of the RTCA system to determine the cytotoxicity of four anticancer agents in carcinoma cells. The results were compared with those of the conventional WST‑8 assay at the endpoint to determine the potential of the RTCA system as a new real‑time assay method to evaluate cytotoxicity. iCELLigence was used as the RTCA system in this study. Suspensions of oral squamous cell carcinoma (OSCC) cell lines were seeded (2x104 cells/well) onto the E‑plate (the culture plate of the iCELLigence system). After 24 h of culture, anticancer agents were added to each well, and changes in electrical impedance (cell index, CI) were recorded for another 72 h of culture. Cell proliferation was detected in real‑time by the RTCA device in an automated, high throughput manner. Then, the IC50 profiles of the four anticancer agents were calculated based on the real‑time cell index values. The results indicated that the RTCA system was useful in evaluating cytotoxic reactions immediately after the addition of the anticancer agents as it was able to record the data in real‑time. Furthermore, the IC50 levels measured by the real‑time assay were lower than those measured by the endpoint assay. Thus, RTCA systems can be used to evaluate chemotherapeutic agents in cancer cells as well as their side effects in normal cells.

Related Articles

Journal Cover

October 2019
Volume 18 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Hazekawa, M., Nishinakagawa, T., Kawakubo‑Yasukochi, T., & Nakashima, M. (2019). Evaluation of IC50 levels immediately after treatment with anticancer reagents using a real‑time cell monitoring device. Experimental and Therapeutic Medicine, 18, 3197-3205. https://doi.org/10.3892/etm.2019.7876
MLA
Hazekawa, M., Nishinakagawa, T., Kawakubo‑Yasukochi, T., Nakashima, M."Evaluation of IC50 levels immediately after treatment with anticancer reagents using a real‑time cell monitoring device". Experimental and Therapeutic Medicine 18.4 (2019): 3197-3205.
Chicago
Hazekawa, M., Nishinakagawa, T., Kawakubo‑Yasukochi, T., Nakashima, M."Evaluation of IC50 levels immediately after treatment with anticancer reagents using a real‑time cell monitoring device". Experimental and Therapeutic Medicine 18, no. 4 (2019): 3197-3205. https://doi.org/10.3892/etm.2019.7876